TP53 and non-small cell lung carcinoma: Another primary purpose of this study was to explore the impact of TP53 mutations on clinical outcomes in NSCLC patients with EGFR-mutation treated with first-line TKIs, and the DCR in patients with EGFR&TP53 co-alterations was lower than that in patients with EGFR mutations (p = 0.0608).